Published in J Immunol on July 11, 2011
Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol (2012) 0.96
Protective CD8 memory T cell responses to mouse melanoma are generated in the absence of CD4 T cell help. PLoS One (2011) 0.93
Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization. J Immunol (2013) 0.89
Epitope-optimized alpha-fetoprotein genetic vaccines prevent carcinogen-induced murine autochthonous hepatocellular carcinoma. Hepatology (2014) 0.80
Engineering α-fetoprotein-based gene vaccines to prevent and treat hepatocellular carcinoma: review and future prospects. Immunotherapy (2014) 0.78
Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity. Mol Ther (2017) 0.77
Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. J Invest Dermatol (2015) 0.77
Diminished Memory T-Cell Expansion Due to Delayed Kinetics of Antigen Expression by Lentivectors. PLoS One (2013) 0.75
Cancer immunotherapy: moving beyond current vaccines. Nat Med (2004) 17.61
Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol (2003) 15.51
Requirement for CD4 T cell help in generating functional CD8 T cell memory. Science (2003) 10.22
Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science (2009) 8.80
Transfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia. Nature (2010) 6.95
Differential requirements for survival and proliferation of CD8 naïve or memory T cells. Science (1997) 6.28
Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol (2006) 5.58
Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A (2004) 4.93
Helping the CD8(+) T-cell response. Nat Rev Immunol (2004) 4.90
Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med (2003) 4.64
Accelerated CD8+ T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med (2005) 4.45
Gene transfer in humans using a conditionally replicating lentiviral vector. Proc Natl Acad Sci U S A (2006) 4.23
From vaccines to memory and back. Immunity (2010) 3.30
Cancer immunotherapy by dendritic cells. Immunity (2008) 3.09
Melanoma mouse model implicates metabotropic glutamate signaling in melanocytic neoplasia. Nat Genet (2003) 2.67
DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol (2000) 2.65
Cutting edge: emergence of CD127high functionally competent memory T cells is compromised by high viral loads and inadequate T cell help. J Immunol (2005) 2.61
Jump-starting the immune system: prime-boosting comes of age. Trends Immunol (2004) 2.61
The role of programming in memory T-cell development. Curr Opin Immunol (2004) 2.41
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res (2007) 2.38
CD8 lethargy in the absence of CD4 help. Eur J Immunol (2002) 1.98
Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity (2006) 1.95
A single heteroclitic epitope determines cancer immunity after xenogeneic DNA immunization against a tumor differentiation antigen. J Immunol (2003) 1.81
Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer. Cancer Prev Res (Phila) (2010) 1.75
In vivo administration of a lentiviral vaccine targets DCs and induces efficient CD8(+) T cell responses. J Clin Invest (2003) 1.54
A default pathway of memory CD8 T cell differentiation after dendritic cell immunization is deflected by encounter with inflammatory cytokines during antigen-driven proliferation. J Immunol (2009) 1.50
The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors. Cancer Res (2001) 1.47
T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J Immunol (1998) 1.44
Immunization with lentiviral vector-transduced dendritic cells induces strong and long-lasting T cell responses and therapeutic immunity. J Immunol (2005) 1.39
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res (1999) 1.28
Intravenous injection of a lentiviral vector encoding NY-ESO-1 induces an effective CTL response. J Immunol (2004) 1.26
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Helper T cells, dendritic cells and CTL Immunity. Immunol Cell Biol (2004) 1.14
Immunoprevention of cancer: is the time ripe? Cancer Res (2000) 1.09
Mini-review CD4 T cells are required for CD8 T cell memory generation. Eur J Immunol (2003) 1.05
Efficient induction of tumor antigen-specific CD8+ memory T cells by recombinant lentivectors. Cancer Res (2006) 1.03
Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol (2001) 1.02
Recombinant viral vectors: cancer vaccines. Adv Drug Deliv Rev (2006) 0.99
Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol (2009) 0.99
Prophylactic cancer vaccines. Curr Opin Immunol (2002) 0.99
Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine (2007) 0.95
Prevention of spontaneous neu-expressing mammary tumor development in mice transgenic for rat proto-neu by DNA vaccination. Gene Ther (2001) 0.93
The role of skin-derived dendritic cells in CD8+ T cell priming following immunization with lentivectors. J Immunol (2010) 0.93
Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope. Vaccine (2009) 0.86
T-cell epitope peptide vaccines. Expert Rev Vaccines (2004) 0.85
Timely DNA vaccine combined with systemic IL-12 prevents parotid carcinomas before a dominant-negative p53 makes their growth independent of HER-2/neu expression. J Immunol (2006) 0.84
Vaccine prevention of cancer: can endogenous antigens be targeted? Cancer Prev Res (Phila) (2010) 0.83
The ultimate in cancer chemoprevention: cancer vaccines. Cancer Prev Res (Phila) (2010) 0.81
Robot-assisted minimally invasive distal pancreatectomy is superior to the laparoscopic technique. Ann Surg (2013) 3.94
Estimating accuracy of RNA-Seq and microarrays with proteomics. BMC Genomics (2009) 3.87
Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice. Immunity (2010) 3.35
Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes. Blood (2009) 2.88
Robotic versus laparoscopic hepatectomy: a matched comparison. Ann Surg (2014) 2.58
Meckel's diverticulum--a high-risk region for malignancy in the ileum. Insights from a population-based epidemiological study and implications in surgical management. Ann Surg (2011) 2.56
Downregulation of miR-133 and miR-590 contributes to nicotine-induced atrial remodelling in canines. Cardiovasc Res (2009) 2.54
MicroRNA, mRNA, and protein expression link development and aging in human and macaque brain. Genome Res (2010) 2.44
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest (2007) 2.36
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol (2003) 2.05
Oncolytic virotherapy: molecular targets in tumor-selective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta (2008) 1.82
Robotic-assisted major pancreatic resection and reconstruction. Arch Surg (2010) 1.82
Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. Cancer (2010) 1.70
Identification of functional genetic variants in cyclooxygenase-2 and their association with risk of esophageal cancer. Gastroenterology (2005) 1.67
Clinical, genetic and radiographic analysis of 108 patients with von Hippel-Lindau disease (VHL) manifested by pancreatic neuroendocrine neoplasms (PNETs). Surgery (2007) 1.67
Oncolytic viruses as therapeutic cancer vaccines. Mol Cancer (2013) 1.64
Multivisceral resection does not affect morbidity and survival after cytoreductive surgery and chemoperfusion for carcinomatosis from colorectal cancer. Ann Surg Oncol (2008) 1.52
Reoperation for parathyroid adenoma: a contemporary experience. Surgery (2009) 1.50
Phase II study of gemcitabine and erlotinib as adjuvant therapy for patients with resected pancreatic cancer. Ann Surg Oncol (2010) 1.48
Medullary carcinoma of the large intestine: a population based analysis. Int J Oncol (2010) 1.47
NF-κB hyperactivation in tumor tissues allows tumor-selective reprogramming of the chemokine microenvironment to enhance the recruitment of cytolytic T effector cells. Cancer Res (2012) 1.46
Phase II study of induction fixed-dose rate gemcitabine and bevacizumab followed by 30 Gy radiotherapy as preoperative treatment for potentially resectable pancreatic adenocarcinoma. Ann Surg Oncol (2013) 1.46
High mobility group box I (HMGB1) release from tumor cells after treatment: implications for development of targeted chemoimmunotherapy. J Immunother (2007) 1.45
Platinums sensitize human epithelial tumor cells to lymphotoxin alpha by inhibiting NFkappaB-dependent transcription. Cancer Biol Ther (2008) 1.44
MicroRNA expression and regulation in human, chimpanzee, and macaque brains. PLoS Genet (2011) 1.40
Oncolytic virus and anti-4-1BB combination therapy elicits strong antitumor immunity against established cancer. Cancer Res (2012) 1.36
The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res (2005) 1.34
Advanced oxidation protein products activate vascular endothelial cells via a RAGE-mediated signaling pathway. Antioxid Redox Signal (2008) 1.27
Chemokine expression from oncolytic vaccinia virus enhances vaccine therapies of cancer. Mol Ther (2011) 1.26
Widespread splicing changes in human brain development and aging. Mol Syst Biol (2013) 1.23
250 robotic pancreatic resections: safety and feasibility. Ann Surg (2013) 1.23
Hepatic abscess in patients with chronic granulomatous disease. Ann Surg (2002) 1.22
Aggressive surgical management of peritoneal carcinomatosis with low mortality in a high-volume tertiary cancer center. Ann Surg Oncol (2007) 1.21
Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther (2004) 1.21
Role for Kruppel-like factor 4 in determining the outcome of p53 response to DNA damage. Cancer Res (2009) 1.16
C-stage in colon cancer: implications of carcinoembryonic antigen biomarker in staging, prognosis, and management. J Natl Cancer Inst (2011) 1.16
Injectable biodegradable temperature-responsive PLGA-PEG-PLGA copolymers: synthesis and effect of copolymer composition on the drug release from the copolymer-based hydrogels. Int J Pharm (2005) 1.15
Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization. J Immunol (2010) 1.15
Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel. Clin Pharmacol Ther (2002) 1.14
Pharmacokinetics of 1alpha,25-dihydroxyvitamin D3 in normal mice after systemic exposure to effective and safe antitumor doses. Oncology (2004) 1.12
Aggressive management of peritoneal carcinomatosis from mucinous appendiceal neoplasms. Ann Surg Oncol (2012) 1.12
Natural killer-dendritic cell cross-talk in cancer immunotherapy. Expert Opin Biol Ther (2005) 1.11
The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther (2005) 1.10
Rapid metabolic evolution in human prefrontal cortex. Proc Natl Acad Sci U S A (2011) 1.09
Treatment factors associated with long-term survival after cytoreductive surgery and regional chemotherapy for patients with malignant peritoneal mesothelioma. Surgery (2013) 1.09
Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep) (2011) 1.08
High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol (2006) 1.07
Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. J Am Coll Surg (2002) 1.07
c-Cbl acts as a mediator of Src-induced activation of the PI3K-Akt signal transduction pathway during TRAIL treatment. Cell Signal (2010) 1.05
Mechanisms of azole resistance in 52 clinical isolates of Candida tropicalis in China. J Antimicrob Chemother (2012) 1.05
Incidence, risk factors for amputation among patients with diabetic foot ulcer in a Chinese tertiary hospital. Diabetes Res Clin Pract (2011) 1.04
Effects of sleep and sleep deprivation on immunoglobulins and complement in humans. Brain Behav Immun (2006) 1.04
Robotic-assisted major pancreatic resection. Adv Surg (2011) 1.03
Hyperthermic isolated hepatic perfusion using melphalan for patients with ocular melanoma metastatic to liver. Clin Cancer Res (2003) 1.01
Three epigenetic drugs up-regulate homeobox gene Rhox5 in cancer cells through overlapping and distinct molecular mechanisms. Mol Pharmacol (2009) 1.01
Ex situ resection techniques and liver autotransplantation: last resource for otherwise unresectable malignancy. Dig Dis Sci (2005) 1.01
Life after death: targeting high mobility group box 1 in emergent cancer therapies. Am J Cancer Res (2013) 1.01
Gadd45b and Gadd45g are important for anti-tumor immune responses. Eur J Immunol (2009) 1.00
A phase I study of hyperthermic isolated hepatic perfusion with oxaliplatin in the treatment of unresectable liver metastases from colorectal cancer. Ann Surg Oncol (2008) 1.00
Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Ann Surg Oncol (2014) 0.99
Gene transfer: the challenge of regulated gene expression. Trends Mol Med (2008) 0.99
Melanoma cell expression of CD200 inhibits tumor formation and lung metastasis via inhibition of myeloid cell functions. PLoS One (2012) 0.99
Beam bending via plasmonic lenses. Opt Express (2010) 0.99
Development of a replication-selective, oncolytic poxvirus for the treatment of human cancers. Cancer Gene Ther (2002) 0.99
Lentivector immunization stimulates potent CD8 T cell responses against melanoma self-antigen tyrosinase-related protein 1 and generates antitumor immunity in mice. J Immunol (2009) 0.99
Vaccinia as a vector for gene delivery. Expert Opin Biol Ther (2004) 0.99
Ultrasound-guided biopsy of greater omentum: an effective method to trace the origin of unclear ascites. Eur J Radiol (2008) 0.99
Neuroendocrine tumors of the pancreas in von Hippel-Lindau disease: spectrum of appearances at CT and MR imaging with histopathologic comparison. Radiology (2002) 0.98
Results of initial operation for hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Surgery (2003) 0.97
Antimicrobial susceptibility and resistance mechanisms of clinical Clostridium difficile from a Chinese tertiary hospital. Int J Antimicrob Agents (2012) 0.97
Silencing suppressors: viral weapons for countering host cell defenses. Protein Cell (2011) 0.97
A novel nomogram for peritoneal mesothelioma predicts survival. Ann Surg Oncol (2012) 0.96
Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects. Mol Ther (2012) 0.96
Targeting vaccinia to solid tumors with local hyperthermia. Hum Gene Ther (2005) 0.95
Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Ann Surg Oncol (2013) 0.95
Intravenous and isolated limb perfusion delivery of wild type and a tumor-selective replicating mutant vaccinia virus in nonhuman primates. Hum Gene Ther (2006) 0.95
Sodium caprate augments the hypoglycemic effect of berberine via AMPK in inhibiting hepatic gluconeogenesis. Mol Cell Endocrinol (2012) 0.94
c-Cbl-mediated degradation of TRAIL receptors is responsible for the development of the early phase of TRAIL resistance. Cell Signal (2010) 0.94
Medium optimization for the production of cyclic adenosine 3',5'-monophosphate by Microbacterium sp. no. 205 using response surface methodology. Bioresour Technol (2008) 0.94
Androgen stimulates endothelial cell proliferation via an androgen receptor/VEGF/cyclin A-mediated mechanism. Am J Physiol Heart Circ Physiol (2011) 0.94
Lentivector expressing HBsAg and immunoglobulin Fc fusion antigen induces potent immune responses and results in seroconversion in HBsAg transgenic mice. Vaccine (2011) 0.92
Operative management of Cushing syndrome secondary to micronodular adrenal hyperplasia. Surgery (2008) 0.92
Minimally invasive liver resection: robotic versus laparoscopic left lateral sectionectomy. J Gastrointest Surg (2012) 0.91